1. Home
  2. PHAR vs ETJ Comparison

PHAR vs ETJ Comparison

Compare PHAR & ETJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • ETJ
  • Stock Information
  • Founded
  • PHAR 1988
  • ETJ 2007
  • Country
  • PHAR Netherlands
  • ETJ United States
  • Employees
  • PHAR N/A
  • ETJ N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • ETJ Finance Companies
  • Sector
  • PHAR Health Care
  • ETJ Finance
  • Exchange
  • PHAR Nasdaq
  • ETJ Nasdaq
  • Market Cap
  • PHAR 951.7M
  • ETJ 603.7M
  • IPO Year
  • PHAR N/A
  • ETJ N/A
  • Fundamental
  • Price
  • PHAR $14.60
  • ETJ $8.96
  • Analyst Decision
  • PHAR Strong Buy
  • ETJ
  • Analyst Count
  • PHAR 3
  • ETJ 0
  • Target Price
  • PHAR $30.00
  • ETJ N/A
  • AVG Volume (30 Days)
  • PHAR 12.7K
  • ETJ 175.6K
  • Earning Date
  • PHAR 10-23-2025
  • ETJ 01-01-0001
  • Dividend Yield
  • PHAR N/A
  • ETJ 8.30%
  • EPS Growth
  • PHAR N/A
  • ETJ N/A
  • EPS
  • PHAR N/A
  • ETJ N/A
  • Revenue
  • PHAR $339,836,000.00
  • ETJ N/A
  • Revenue This Year
  • PHAR $16.63
  • ETJ N/A
  • Revenue Next Year
  • PHAR $6.77
  • ETJ N/A
  • P/E Ratio
  • PHAR N/A
  • ETJ N/A
  • Revenue Growth
  • PHAR 22.44
  • ETJ N/A
  • 52 Week Low
  • PHAR $7.31
  • ETJ $7.20
  • 52 Week High
  • PHAR $17.08
  • ETJ $8.47
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 56.71
  • ETJ 44.83
  • Support Level
  • PHAR $13.63
  • ETJ $8.94
  • Resistance Level
  • PHAR $15.27
  • ETJ $9.04
  • Average True Range (ATR)
  • PHAR 0.96
  • ETJ 0.07
  • MACD
  • PHAR -0.13
  • ETJ -0.01
  • Stochastic Oscillator
  • PHAR 51.83
  • ETJ 28.26

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

Share on Social Networks: